- Home
- MBCN vs OBIO Comparison
MBCN vs OBIO Comparison
Compare MBCN & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBCN | OBIO |
|---|---|---|
| Founded | 1901 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.8M | 246.2M |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MBCN | OBIO |
|---|---|---|
| Price | $33.67 | $4.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $35.00 | $14.25 |
| AVG Volume (30 Days) | 37.5K | ★ 194.2K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.01 | N/A |
| Revenue | N/A | ★ $2,638,000.00 |
| Revenue This Year | $8.35 | $36.66 |
| Revenue Next Year | $6.67 | $2.30 |
| P/E Ratio | $16.73 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.74 | $2.20 |
| 52 Week High | $37.68 | $5.42 |
Technical Indicators
Market Signals| Indicator | MBCN | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 42.79 | 60.40 |
| Support Level | $33.51 | $4.00 |
| Resistance Level | $34.19 | $5.00 |
| Average True Range (ATR) | 0.81 | 0.25 |
| MACD | -0.05 | 0.06 |
| Stochastic Oscillator | 18.83 | 85.43 |
Price Performance
Historical ComparisonAbout MBCN Middlefield Banc Corp.
Middlefield Banc Corp is a bank holding company. It offers customers, banking services including checking, savings, negotiable order of withdrawal (NOW) accounts, money market accounts, time deposits, commercial loans, real estate loans, a variety of consumer loans, safe deposit facilities, and travelers' checks. It also provides online banking and bill payment services to individuals and online cash management services to business customers.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.